Novartis AG – Strategy, SWOT and Corporate Finance Report

Novartis AG – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Scope

Detailed information on Novartis AG required for business and competitor intelligence needs

A study of the major internal and external factors affecting Novartis AG in the form of a SWOT analysis

An in-depth view of the business model of Novartis AG including a breakdown and examination of key business segments

News about Novartis AG, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Novartis AG and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Novartis AG as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Novartis AGs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

SwitchGear Genomics Inc

Sanofi

Pfizer Inc

Novo Nordisk AS

Merck & Co Inc

Johnson & Johnson

GlaxoSmithKline Plc

Flarer SA

F. Hoffmann-La Roche Ltd

Eli Lilly and Co

Bristol-Myers Squibb Co

AstraZeneca Plc

Amgen Inc

AbbVie Inc

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Novartis AG - Key Facts

Novartis AG - Key Employees

Novartis AG - Key Employee Biographies

Novartis AG - Major Products and Services

Novartis AG - History

Novartis AG - Company Statement

Novartis AG - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 Company Analysis

Company Overview

Novartis AG - Business Description

Business Segment: Alcon

Overview

Performance

Key Stats

Business Segment: Innovative Medicines

Overview

Performance

Key Stats

Business Segment: Sandoz

Overview

Performance

Key Stats

Geographical Segment: Americas

Target Markets

Performance

Geographical Segment: Asia/Africa/Australasia

Performance

Geographical Segment: Europe

Target Markets

Performance

R&D Overview

Novartis AG - Corporate Strategy

Novartis AG - SWOT Analysis

SWOT Analysis - Overview

Novartis AG - Strengths

Novartis AG - Weaknesses

Novartis AG - Opportunities

Novartis AG - Threats

Novartis AG - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Novartis AG, Recent Deals Summary

Section 5 Company’s Recent Developments

Feb 11, 2019: Recro Pharma announces five-year manufacturing and supply agreement between Novartis and Recro Gainesville

Jan 30, 2019: Aduro Biotech announces strategic reset

Jan 28, 2019: Novartis stockpiles medicines ahead of Brexit

Jan 21, 2019: Novartis chooses Kinaxis’ technology to improve supply chain planning

Jan 18, 2019: Novartis and University of Oxford partner on AI-based drug development

Jan 10, 2019: Novartis response to NICE Appraisal Consultation Document (ACD) for Aimovig&174; (erenumab) for the prevention of migraine

Jan 09, 2019: Adimab provides 2018 update on clinical pipeline

Jan 08, 2019: Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

Dec 21, 2018: Novartis makes offer to acquire French CDMO CellforCure

Dec 20, 2018: Novartis announces new CEO of Oncology Business Unit

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Novartis AG, Key Facts

Novartis AG, Key Employees

Novartis AG, Key Employee Biographies

Novartis AG, Major Products and Services

Novartis AG, History

Novartis AG, Subsidiaries

Novartis AG, Key Competitors

Novartis AG, Ratios based on current share price

Novartis AG, Annual Ratios

Novartis AG, Annual Ratios (Cont…1)

Novartis AG, Annual Ratios (Cont…2)

Novartis AG, Interim Ratios

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Novartis AG, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Novartis AG, Performance Chart (2014 – 2018)

Novartis AG, Ratio Charts

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports